Acuta Capital Partners, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Acuta Capital Partners, LLC reported 27 stock positions worth $71.6 million. Its top holding was Ocular Therapeutix (OCUL) at 13.2% of the portfolio, followed by Cidara Therapeutics (CDTX, 12.2%) and Whitehawk Therapeutics (WHWK, 8.9%). Compared with Q1 2025, it opened 3 new positions, sold out of 9, added to 6 and reduced 14. The biggest buy was Cidara Therapeutics (CDTX, shares +43%) and the biggest sale an exit from Enliven Therapeutics (ELVN).
- Most Recent 13F
- Q2 2026
- Location
- REDWOOD CITY, CA
- CIK
- 0001582844
- Portfolio Value
- $71.6M (Q2 2025)
- SEC Filing
- 0001104659-25-078732 ↗ filed Aug 14, 2025
Holdings Value
Holdings 27 stocks · $71.6M
| OCUL Ocular Therapeutix Inc. | 13.15% | 1,014,940 | $9.4M | Reduce -16.8% |
| CDTX Cidara Therapeutics Inc. | 12.21% | 179,569 | $8.7M | Add +42.9% |
| WHWK Whitehawk Therapeutics Inc. | 8.91% | 3,410,402 | $6.4M | No change |
| SLNO Soleno Therapeutics Inc. | 7.42% | 63,436 | $5.3M | Reduce -5.5% |
| TRML Tourmaline Bio Inc. | 6.33% | 283,682 | $4.5M | Reduce -33.5% |
| ASND Ascendis Pharma A/S | 5.44% | 22,576 | $3.9M | Reduce -3.3% |
| INSM Insmed Inc. | 5.21% | 37,070 | $3.7M | Reduce -65.0% |
| ARGX Argenx SE - ADR | 5.16% | 6,702 | $3.7M | Reduce -4.6% |
| PRAX Praxis Precision Medicines I | 4.35% | 74,087 | $3.1M | Reduce -15.0% |
| JAZZ Jazz Pharmaceuticals PLC | 3.89% | 26,283 | $2.8M | Add +174.5% |
| TRVI Trevi Therapeutics Inc. | 3.77% | 493,735 | $2.7M | Reduce -37.2% |
| OCS Oculis Holding AG | 2.89% | 106,718 | $2.1M | Reduce -14.6% |
| RVMD Revolution Medicines Inc. | 2.86% | 55,693 | $2.0M | Reduce -16.4% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 2.78% | 187,257 | $2.0M | No change |
| TERN Terns Pharmaceuticals Inc. | 2.42% | 463,864 | $1.7M | Add +42.5% |
| SRZN Surrozen Inc. | 2.12% | 170,000 | $1.5M | No change |
| DRUG Bright Minds Biosciences Inc. | 1.77% | 48,474 | $1.3M | Reduce -18.9% |
| TSHA Taysha Gene Therapies Inc. | 1.57% | 485,669 | $1.1M | New |
| AKRO Akero Therapeutics Inc. | 1.47% | 19,772 | $1.1M | New |
| ZYME Zymeworks Inc. | 1.47% | 83,655 | $1.0M | Add +22.2% |
| LQDA Liquidia Corp. | 1.32% | 75,876 | $945K | Reduce -50.6% |
| RARE Ultragenyx Pharmaceutical Inc. | 1.21% | 23,814 | $866K | Add +11.9% |
| VSTM Verastem Inc. | 0.87% | 150,414 | $624K | Reduce -14.5% |
| FULC Fulcrum Therapeutics Inc. | 0.57% | 59,650 | $410K | New |
| UNCY Unicycive Therapeutics Inc. | 0.42% | 62,899 | $300K | Reduce -73.3% |
| RAPP Rapport Therapeutics Inc. | 0.32% | 20,000 | $227K | Add +21.9% |
| ARTV Artiva Biotherapeutics Inc. | 0.10% | 45,456 | $69K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $25K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 90,832 | $25K | No change |
Total filed on the 13F, all lines: $71.6M.
Portfolio Sells Q1 2025 → Q2 2025
| ELVN Enliven Therapeutics Inc. | Sold out | 0.00% | −6.06 |
| INSM Insmed Inc. | Reduce -65.0% | 5.21% | −4.18 |
| MRK Merck & Co. Inc. | Sold out | 0.00% | −2.39 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −2.18 |
| MREO Mereo Biopharma Group PL-ADR | Sold out | 0.00% | −2.07 |
| TRVI Trevi Therapeutics Inc. | Reduce -37.2% | 3.77% | −1.96 |
| LQDA Liquidia Corp. | Reduce -50.6% | 1.32% | −1.31 |
| GILD Gilead Sciences Inc. | Sold out | 0.00% | −1.21 |
| TRML Tourmaline Bio Inc. | Reduce -33.5% | 6.33% | −1.20 |
| UNCY Unicycive Therapeutics Inc. | Reduce -73.3% | 0.42% | −1.15 |
| VERV Verve Therapeutics Inc. | Sold out | 0.00% | −0.86 |
| DRUG Bright Minds Biosciences Inc. | Reduce -18.9% | 1.77% | −0.73 |
| RCKT Rocket Pharmaceuticals Inc. | Sold out | 0.00% | −0.64 |
| VSTM Verastem Inc. | Reduce -14.5% | 0.87% | −0.36 |
| FBRX Forte Biosciences Inc. | Sold out | 0.00% | −0.17 |
| ENLIVEN THERAPEUTICS INC | Sold out | 0.00% | 0.00 |
| RVMD Revolution Medicines Inc. | Reduce -16.4% | 2.86% | +0.13 |
| OCS Oculis Holding AG | Reduce -14.6% | 2.89% | +0.13 |
| ARGX Argenx SE - ADR | Reduce -4.6% | 5.16% | +0.34 |
| PRAX Praxis Precision Medicines I | Reduce -15.0% | 4.35% | +0.52 |
| ASND Ascendis Pharma A/S | Reduce -3.3% | 5.44% | +1.22 |
| SLNO Soleno Therapeutics Inc. | Reduce -5.5% | 7.42% | +1.86 |
| OCUL Ocular Therapeutix Inc. | Reduce -16.8% | 13.15% | +2.78 |
Portfolio Buys Q1 2025 → Q2 2025
| CDTX Cidara Therapeutics Inc. | Add +42.9% | 12.21% | +9.07 |
| JAZZ Jazz Pharmaceuticals PLC | Add +174.5% | 3.89% | +2.52 |
| TSHA Taysha Gene Therapies Inc. | New | 1.57% | +1.57 |
| AKRO Akero Therapeutics Inc. | New | 1.47% | +1.47 |
| TERN Terns Pharmaceuticals Inc. | Add +42.5% | 2.42% | +1.37 |
| FULC Fulcrum Therapeutics Inc. | New | 0.57% | +0.57 |
| ZYME Zymeworks Inc. | Add +22.2% | 1.47% | +0.52 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +11.9% | 1.21% | +0.31 |
| RAPP Rapport Therapeutics Inc. | Add +21.9% | 0.32% | +0.13 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $143.5M | PRAX, WHWK, TNGX, STRO, AVBP |
| Q1 2026 | 26 | $140.6M | PRAX, TERN, WHWK, TNGX, DRUG |
| Q4 2025 | 29 | $147.3M | TERN, PRAX, CDTX, OCUL, WHWK |
| Q3 2025 | 27 | $96.8M | OCUL, CDTX, TRML, WHWK, INSM |
| Q2 2025 | 27 | $71.6M | OCUL, CDTX, WHWK, SLNO, TRML |
| Q1 2025 | 33 | $86.2M | OCUL, INSM, TRML, WHWK, ELVN |
| Q4 2024 | 38 | $99.4M | OCUL, INSM, TRML, CRNX, ELVN |
| Q3 2024 | 40 | $123.5M | PCVX, OCUL, TRML, INSM, ELVN |
| Q2 2024 | 31 | $118.6M | OCUL, ELVN, PCVX, DYN, PRAX |
| Q1 2024 | 32 | $153.9M | OCUL, PRAX, MERSANA THERAPEUTICS INC, TSHA, RCKT |